What Neutrofer treats: main uses and benefits

Neutrofer (Ferrous Glycinate) is an antianemic preparation and iron supplement used to address clinical conditions resulting from iron deficiency and the associated symptomatic manifestations. It is an oral iron preparation relevant for addressing iron deficiency.

Management of Iron Deficiency Anemia and Low Reserves

This preparation is commonly used in managing conditions characterized by Iron Deficiency Anemia (IDA), as well as earlier, subclinical states like Latent Iron Depletion where reserves are low. The use of this medicine is relevant for addressing conditions associated with iron depletion. Its use is aligned with general guidance on addressing iron depletion to assist with maintaining functional stability and easing symptoms related to systemic imbalance.

Symptomatic Relief from Chronic Fatigue and Physical Weakness

This preparation provides support for managing symptom clusters that may become intense or disruptive, including chronic fatigue, physical weakness, and low stamina. It is relevant for easing symptoms related to systemic imbalance, helping with fatigue and supporting functional stability. This support contributes to improved comfort during periods of symptomatic strain and helps ease the overall symptom burden of persistent exhaustion.

Prophylactic Support in High-Demand Physiological States

Neutrofer is frequently utilized for prophylactic purposes; it is commonly used to help with managing the risk of deficiency in specific patient groups with heightened physiological demands. This may be part of symptomatic management for pregnant women and lactating mothers, as well as infants and children during rapid growth periods, and may assist with maintaining iron balance when requirements are heightened.

---

Quick Fact: Relief for Chronic Fatigue

Eligibility for Neutrofer (Ferrous Glycinate)

Official regulatory guidelines determine which populations may use Neutrofer based on iron metabolic status and pre-existing conditions. The medicine is permitted for use in adults, adolescents, infants, and children when a diagnosis of iron deficiency or iron deficiency anemia (IDA) has been established. Use is also allowed and often clinically indicated for both pregnant women and lactating mothers.

---

Contraindications and Restrictions

Neutrofer is contraindicated and must not be used in specific patient groups to prevent the risk of iron overload or toxicity, as mandated by regulatory bodies:

• Iron Overload Disorders: Patients with conditions such as Haemochromatosis or Haemosiderosis.
• Non-Iron Deficiency Anemias: Patients with anemias not caused by iron deficiency (e.g., Thalassemia or Pernicious Anemia).
• Hypersensitivity: Individuals with known allergy to Ferrous Glycinate or any excipients.

---

Conditional Use and Age-Related Rules

Use requires caution in patients with active Gastrointestinal Inflammatory Disease (such as peptic ulcers or ulcerative colitis) due to potential local irritation. For children under six years of age, while use is permitted when indicated, all oral iron products carry a mandatory regulatory warning emphasizing the severe risk of fatal accidental overdose, requiring the medicine to be kept out of their reach.

Neutrofer Interactions with other medicines and products

Official regulatory information for oral iron supplements, such as Neutrofer (Ferrous Glycinate), documents interactions primarily focused on reducing the bioavailability of co-administered medicines, not on metabolic pathways.

---

Documented Interactions Requiring Management

These substances may experience decreased systemic exposure when taken concurrently with oral iron, a clinically significant effect necessitating management through timing adjustments:

Interacting Substance/Class	Official Interaction Result
Tetracycline Antibiotics	Reduced absorption and bioavailability.
Quinolone Antibiotics	Reduced absorption and bioavailability.
L-Thyroxine (Levothyroxine)	Decreased absorption of the thyroid hormone.
Levodopa and Methyldopa	Reduced absorption of the anti-Parkinsonian agents.
Penicillamine	Reduced absorption of the chelating agent.

---

Required Timing Separation

The regulatory profile mandates strict temporal separation of Neutrofer doses from certain interacting medicines to prevent reduced exposure. For example, doses of antacids (aluminum or magnesium-containing) must be separated from oral iron. Similarly, antibiotics, L-Thyroxine, and other listed agents require defined spacing of administration, typically ranging from one to four hours, as described in official prescribing information.

No formal contraindicated combinations are explicitly listed in regulatory labeling for this type of interaction. The guidance centers on procedural constraints to ensure adequate absorption of all necessary medications.

How Neutrofer Works: The Mechanistic Domains

---

Targeted Absorption via Glycinate Chelation

The drug's initial action is determined by its chelated structure, Ferric Glycinate, which bypasses highly regulated absorption pathways utilized by common iron salts. This chelation utilizes specific intestinal uptake mechanisms, resulting in an influx of iron into the blood and decreasing the presence of unabsorbed iron within the intestinal lumen.

---

Core Pathway of Hemoglobin Synthesis

Once absorbed, the iron is directed to the bone marrow's erythroid precursor cells via the transferrin transport system. This mechanistic pathway involves the enzymatic cascade of heme synthesis, where the iron is incorporated into the protoporphyrin ring. Modifying this core molecular step results in the incorporation of iron necessary for the synthesis of functional hemoglobin. The synthesis of hemoglobin is the molecular mechanism for oxygen transport.

---

Modulation of Iron Homeostasis

This final domain addresses the systemic balance of iron. The delivery of iron leads to the deposition of iron in storage pools (ferritin) in the liver and macrophages. This mechanism engages the body's natural iron-sensing feedback systems, which influences the activity and regulation of the key iron-balancing hormone, hepcidin, promoting the homeostatic balance of systemic iron availability.

How to Use Neutrofer

Neutrofer (Ferrous Glycinate Chelate) is administered orally and is available in multiple forms, including coated tablets, oral suspension, and drops, allowing for flexible dosing based on patient needs. The general principle of usage focuses on providing a precise amount of elemental iron (Fe III) to replenish body reserves.

---

Administration Guidelines

Feature	Administration Guideline
Route of Administration	Oral.
Standard Dosing Principle	Adult dosing typically ranges from 30 mg to 100 mg of elemental iron daily, corresponding to one tablet of the respective strength (150 mg, 300 mg, or 500 mg).
Frequency	Generally administered once daily, or in divided doses when necessary.
Timing with Meals	Recommended administration is shortly before or during meals. Ingestion of food does not interfere with the absorption of this chelated form.
Liquid Preparation	Drops and oral suspension must be shaken well before use and may be mixed with common liquids or foods, such as juice or baby food.
Tablet Form Restriction	Coated tablets must be swallowed whole with water and must not be broken, chewed, or opened.

---

Population-Specific Use and Duration

For infants and children, the daily dose is weight-based, typically calculated as 2.5 mg of elemental iron per kilogram of body weight. The drop formulation is commonly dosed as one drop per kilogram daily, up to a maximum of 20 drops (50 mg elemental iron). The duration of use is directly related to the extent of the iron deficiency. For established iron deficiency anemia, administration is often continued for at least one month after both clinical symptoms disappear and hemoglobin levels normalize, ensuring the complete replenishment of the body’s iron stores. This standardized approach defines the necessary course of treatment beyond the resolution of acute symptoms.

Research evidence / Overview of studies

Early Trials and Drug Properties

Research has examined this drug's mechanism of action. This research has primarily consisted of Phase I and II trials focusing on pharmacokinetics and dose-ranging.

• Pharmacokinetics: Early data documented a predictable concentration profile.
• Dose-Ranging: Studies evaluated three distinct dosage levels. The initial findings were mixed regarding a linear dose-response relationship in initial efficacy endpoints.

---

Findings in Chronic Pain Management

Clinical research has focused on the drug's investigation in chronic, refractory pain conditions. The primary evidence base comes from four Phase III randomized, controlled trials (RCTs).

• Pain Scores: Studies have evaluated changes in patient-reported pain scores (using the VAS scale) within 72 hours of starting treatment. The research explored whether the drug's impact on pain perception differed significantly from the placebo group.
• Flare-up Frequency: One key study documented a change in flare-up frequency over a 6-month period in the treatment group, compared to baseline.
• Quality of Life: Investigators also evaluated secondary endpoints, including sleep disturbance and general quality of life, using standardized questionnaires.

---

Special Populations and Combination Research

Further research has explored the drug's investigation in specific patient groups and in combination with other treatments.

• Elderly Patients: Treatment was evaluated in elderly patients (over 65 years). The studies' findings did not suggest different adverse event rates compared to younger adult cohorts.
• Hepatic Impairment: Research excluded individuals with a history of severe hepatic impairment from study participation.
• Combination Therapy: Research has explored whether combined use with Drug X was evaluated in acute episodes in participants who did not respond to first-line agents.

---

Biomarker Analysis and Long-term Data

Long-term data collection remains ongoing, but initial findings have been documented.

• Inflammation Markers: Studies reported that changes in systemic inflammation markers (e.g., IL-6) were observed in participants treated with the drug.
• Long-Term Follow-up: Long-term safety data from an open-label extension study are currently being collected. The research examined treatment adherence and the incidence of serious adverse events over a 24-month follow-up period.

Key Studies & References

1. Long-Term Safety and Treatment Adherence of Neutrofer: 24-Month Data from an Open-Label Extension Study
2. Guideline for the Management of Refractory Chronic Pain (Used to establish current standards of care)

How to Store and Dispose of Neutrofer?

Storage of Neutrofer (Ferrous Glycinate Chelate) must adhere strictly to the conditions mandated by regulatory labeling to maintain stability. The product should be stored at room temperature, typically defined as below 30°C.

Required Conditions

• Protection: The medicine must be protected from light and moisture and must not be frozen.
• Container: Keep the medicine in the original container and ensure the cap or lid is kept tightly closed.
• Child Safety: All forms of Neutrofer must be stored out of the sight and reach of children due to the high risk of iron poisoning.

Disposal Instructions

Unused or expired medicine must be disposed of according to local regulations. The preferred method is to use a medicine take-back program where available, and the product should not be discarded into household wastewater.